Effects of Cladribine Tablets on MRI Outcomes in High Disease Activity (HDA) Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study

G. Giovanni1, K. Rammohan2, S. Cook3, G. Comi4, P. Rickmann5, P. Soelberg-Sorensen4, P. Vemurs6, F. Dangond7, C. Hicking

1Queen Mary University of London, London, United Kingdom; 2Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 3Neurosurgery, Cleveland Clinic, Cleveland, Ohio, USA; 4Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 5Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, USA; 6Department of Neurology and Institute of Experimental Neurology, University Vito-Salute San Raffaele, Ospedale San Raffaele, Milan, Italy; 7Department of Neurology, Medical Park Lübeck and University of Lübeck, Lübeck, Germany; 8Danish MS Center, Department of Neurology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark; 9Université de Liège, CHU Liège, URSCI-INSU-UMR 800, Phimez, Lierre, France, 10Koovs Sexens, Inc., Billerica, MA, USA; 11Weill KJGS, Hannover Medical School, Germany

OBJECTIVE

To compare the effects of cladribine tablets 3.5 mg/kg versus placebo on outcomes assessed by magnetic resonance imaging (MRI) in subgroups of CLARITY patients with evidence of HDA activity at study entry, using HDA criteria.

METHODS

The CLARITY study: NCT00213135.

RESULTS

Figure 1. Forest Plot of Relative Risk of Active T2 Lesions by HDA Subgroup for Cladribine Tablets 3.5 mg/kg versus Placebo

CONCLUSIONS

DISCLOSURES

REFERENCES

The CLARITY study: NCT00213135.

ACKNOWLEDGMENTS

Presented at Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2019, May 30 – June 2, Nashville, Tennessee

CONCLUSIONS

In patients with RMS in the CLARITY study, treatment with cladribine tablets 3.5 mg/kg prolonged statistically significant effects versus placebo on cumulative new T1 Gd+ lesions, active T2 lesions, and cumulative CUA lesions in two subgroups of patients selected using HDA criteria.

In each HDA subgroup, there was a consistent treatment effect on radiological outcomes with cladribine tablets 3.5 mg/kg irrespective of disease activity before entry to the CLARITY study, or prior DMD use.

OBJECTIVE

To compare the effects of cladribine tablets 3.5 mg/kg versus placebo on outcomes assessed by magnetic resonance imaging (MRI) in subgroups of CLARITY patients with evidence of HDA activity at study entry, using HDA criteria.

METHODS

The CLARITY study: NCT00213135.

CONCLUSIONS

In patients with RMS in the CLARITY study, treatment with cladribine tablets 3.5 mg/kg prolonged statistically significant effects versus placebo on cumulative new T1 Gd+ lesions, active T2 lesions, and cumulative CUA lesions in two subgroups of patients selected using HDA criteria.

In each HDA subgroup, there was a consistent treatment effect on radiological outcomes with cladribine tablets 3.5 mg/kg irrespective of disease activity before entry to the CLARITY study, or prior DMD use.

REFERENCES

The CLARITY study: NCT00213135.

ACKNOWLEDGMENTS

Presented at Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2019, May 30 – June 2, Nashville, Tennessee

CONCLUSIONS

In patients with RMS in the CLARITY study, treatment with cladribine tablets 3.5 mg/kg prolonged statistically significant effects versus placebo on cumulative new T1 Gd+ lesions, active T2 lesions, and cumulative CUA lesions in two subgroups of patients selected using HDA criteria.

In each HDA subgroup, there was a consistent treatment effect on radiological outcomes with cladribine tablets 3.5 mg/kg irrespective of disease activity before entry to the CLARITY study, or prior DMD use.

OBJECTIVE

To compare the effects of cladribine tablets 3.5 mg/kg versus placebo on outcomes assessed by magnetic resonance imaging (MRI) in subgroups of CLARITY patients with evidence of HDA activity at study entry, using HDA criteria.

METHODS

The CLARITY study: NCT00213135.

RESULTS

Figure 1. Forest Plot of Relative Risk of Active T2 Lesions by HDA Subgroup for Cladribine Tablets 3.5 mg/kg versus Placebo

CONCLUSIONS

In patients with RMS in the CLARITY study, treatment with cladribine tablets 3.5 mg/kg prolonged statistically significant effects versus placebo on cumulative new T1 Gd+ lesions, active T2 lesions, and cumulative CUA lesions in two subgroups of patients selected using HDA criteria.

In each HDA subgroup, there was a consistent treatment effect on radiological outcomes with cladribine tablets 3.5 mg/kg irrespective of disease activity before entry to the CLARITY study, or prior DMD use.

REFERENCES

The CLARITY study: NCT00213135.

ACKNOWLEDGMENTS

Presented at Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2019, May 30 – June 2, Nashville, Tennessee

CONCLUSIONS

In patients with RMS in the CLARITY study, treatment with cladribine tablets 3.5 mg/kg prolonged statistically significant effects versus placebo on cumulative new T1 Gd+ lesions, active T2 lesions, and cumulative CUA lesions in two subgroups of patients selected using HDA criteria.

In each HDA subgroup, there was a consistent treatment effect on radiological outcomes with cladribine tablets 3.5 mg/kg irrespective of disease activity before entry to the CLARITY study, or prior DMD use.